ResearcherJohns Hopkins UniversityActive in the last 2 years
Neeha Zaidi
Matched on ORCID iD 0000-0002-0094-0049; OpenAlex author ID A5015492234; NIH RePORTER profile ID 15171582. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 2, last author 5)
- Trials
- 0
- Grants
- 3
- Labs led
- 1
- Collaborators
- 63
2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers, 1 grant · 2026: 4 papers, 2 grants
Papers 12
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Last author DOI 10.1038/s41467-026-68324-4↗
- Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Last author DOI 10.1038/s41467-026-71968-x↗
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Last author DOI 10.1158/2159-8290.cd-25-2245↗
- Targeting RAS for Pancreatic Cancer Interception. First author DOI 10.1158/2159-8290.cd-26-1179↗
- Emerging Systemic Therapy Considerations for Pancreatic Cancer. Last author DOI 10.1016/j.semradonc.2025.07.006↗
- Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
- Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… Co-author DOI 10.1002/cncr.35479↗
- Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
- Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Co-author DOI 10.1186/s13059-021-02363-6↗
- Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
- Dual Checkpoint Inhibition in Pancreatic Cancer: Revealing the Limitations of Synergy and the Potential of Novel Combinations. First author DOI 10.1001/jamaoncol.2019.1583↗
- Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Last author DOI 10.1172/jci.insight.122857↗
Grants 3
Closest collaborators
The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nilofer Saba Azad · 5 shared papers, 1 shared grant, 2021–2026 · strength 2.15
- Grant Optimization of an active mutant KRAS peptide vaccine in colorectal cancer R01CA296410↗
- Paper Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center… DOI 10.1200/po-24-00494↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Elizabeth M. Jaffee · 7 shared papers, 2018–2026 · strength 1.23
- Paper Targeting RAS for Pancreatic Cancer Interception. DOI 10.1158/2159-8290.cd-26-1179↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Daniel A. Laheru · 6 shared papers, 2020–2026 · strength 1.12
- Paper Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventio… DOI 10.1002/cncr.35479↗
- Paper Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center… DOI 10.1200/po-24-00494↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Mark M. Yarchoan · 6 shared papers, 2018–2026 · strength 0.85
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Won Jin Ho · 5 shared papers, 2021–2026 · strength 0.78
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Marina Baretti · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Luciane Tsukamoto Kagohara · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Amanda L. Huff · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Matthew Z. Guo · 2 shared papers, 2025–2026 · strength 0.63
- Hao Wang · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Katherine M. Bever · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Elana Judith Fertig · 3 shared papers, 2021–2026 · strength 0.48
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific im… DOI 10.1186/s13059-021-02363-6↗
- Michael Jon Pishvaian · 2 shared papers, 2024–2025 · strength 0.45
- Paper Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventio… DOI 10.1002/cncr.35479↗
- Paper Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center… DOI 10.1200/po-24-00494↗
- Kai-li Liang · 1 shared paper, 2025 · strength 0.42
- Hassan Sinan · 2 shared papers, 2025–2026 · strength 0.42
- Michael Goggins · 2 shared papers, 2025–2026 · strength 0.42
- Laura DeLong Wood · 1 shared paper, 2026 · strength 0.39
- Alison P. Klein · 1 shared paper, 2026 · strength 0.39
- Sandra Misale · 1 shared paper, 2026 · strength 0.39
- Jae Woo Lee · 2 shared papers, 2026 · strength 0.38
- Robert A. Anders · 2 shared papers, 2026 · strength 0.38
- Janelle Marie Montagne · 2 shared papers, 2026 · strength 0.38
- Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
- Jin Peng He · 2 shared papers, 2021–2025 · strength 0.31
- Paper Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center… DOI 10.1200/po-24-00494↗
- Paper Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplet… DOI 10.1080/2162402x.2021.2001159↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.